(PHIA) Koninklijke Philips - Ratings and Ratios
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0000009538
Imaging, Monitoring, Homecare, Grooming, Dental
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 31.2% |
| Value at Risk 5%th | 40.4% |
| Relative Tail Risk | -21.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.12 |
| Alpha | -10.08 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.330 |
| Beta | 0.235 |
| Beta Downside | 0.429 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.92% |
| Mean DD | 10.87% |
| Median DD | 9.68% |
Description: PHIA Koninklijke Philips October 14, 2025
Koninklijke Philips N.V. (PHIA) is a global health-technology company organized into three segments: Diagnosis & Treatment, Connected Care, and Personal Health. The firm sells diagnostic imaging equipment (MRI, X-ray, CT, ultrasound), interventional imaging systems, acute and home-care patient-management solutions, as well as consumer health products such as power toothbrushes and infant-care devices.
In FY 2023 Philips reported €22.4 billion in revenue, with the Diagnosis & Treatment segment contributing roughly 55 % of total sales and delivering a 12 % operating margin, while Connected Care grew at a 9 % CAGR over the past three years driven by expanding tele-health adoption. R&D intensity remains high at about 7 % of revenue, reflecting the company’s focus on AI-enabled imaging and software platforms. Key macro drivers include rising US healthcare expenditure (projected to exceed 18 % of GDP by 2027) and accelerating demand for digital and remote patient-monitoring solutions in aging populations.
For a deeper, data-driven assessment of Philips’ valuation and risk profile, you may find the analytics on ValueRay worth a look.
PHIA Stock Overview
| Market Cap in USD | 27,400m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | |
| Return 12m vs S&P 500 | -15.5% |
| Analyst Rating | - |
PHIA Dividends
| Metric | Value |
|---|---|
| Dividend Yield | 3.54% |
| Yield on Cost 5y | 2.54% |
| Yield CAGR 5y | -1.58% |
| Payout Consistency | 79.6% |
| Payout Ratio | 62.0% |
PHIA Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 33.71% |
| CAGR/Max DD Calmar Ratio | 0.99 |
| CAGR/Mean DD Pain Ratio | 3.10 |
| Current Volume | 1180.3k |
| Average Volume | 1299.4k |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (165.0m TTM) > 0 and > 6% of Revenue (6% = 1.07b TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA -3.32pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 12.64% (prev 9.16%; Δ 3.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 1.16b > Net Income 165.0m (YES >=105%, WARN >=100%) |
| Net Debt (6.47b) to EBITDA (1.58b) ratio: 4.09 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.32 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (951.0m) change vs 12m ago 2.05% (target <= -2.0% for YES) |
| Gross Margin 43.49% (prev 42.18%; Δ 1.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 63.46% (prev 60.74%; Δ 2.72pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 2.49 (EBITDA TTM 1.58b / Interest Expense TTM 297.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.35
| (A) 0.09 = (Total Current Assets 9.28b - Total Current Liabilities 7.03b) / Total Assets 26.34b |
| (B) 0.12 = Retained Earnings (Balance) 3.21b / Total Assets 26.34b |
| (C) 0.03 = EBIT TTM 739.0m / Avg Total Assets 28.02b |
| (D) 0.20 = Book Value of Equity 3.21b / Total Liabilities 15.76b |
| Total Rating: 1.35 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 43.24
| 1. Piotroski 3.50pt |
| 2. FCF Yield 0.57% |
| 3. FCF Margin 0.98% |
| 4. Debt/Equity 0.79 |
| 5. Debt/Ebitda 4.09 |
| 6. ROIC - WACC (= -2.57)% |
| 7. RoE 1.48% |
| 8. Rev. Trend -36.05% |
| 9. EPS Trend 6.31% |
What is the price of PHIA shares?
As of November 26, 2025, the stock is trading at EUR 24.02 with a total of 1,180,269 shares traded.
Over the past week, the price has changed by +1.48%, over one month by -3.34%, over three months by +0.76% and over the past year by -3.39%.
Over the past week, the price has changed by +1.48%, over one month by -3.34%, over three months by +0.76% and over the past year by -3.39%.
Is PHIA a buy, sell or hold?
Koninklijke Philips has no consensus analysts rating.
What are the forecasts/targets for the PHIA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27 | 12.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 23.3 | -3.1% |
PHIA Fundamental Data Overview November 18, 2025
Market Cap USD = 27.40b (23.80b EUR * 1.1511 EUR.USD)
Market Cap EUR = 23.80b (23.80b EUR * 1.0 EUR.EUR)
P/E Trailing = 154.875
P/E Forward = 15.1976
P/S = 1.3388
P/B = 2.2333
P/EG = 0.3634
Beta = 0.907
Revenue TTM = 17.78b EUR
EBIT TTM = 739.0m EUR
EBITDA TTM = 1.58b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortLongTermDebt, last quarter)
Debt = 8.38b EUR (Calculated: Short Term 1.15b + Long Term 7.24b)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 30.28b EUR (23.80b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 2.49 (Ebit TTM 739.0m / Interest Expense TTM 297.0m)
FCF Yield = 0.57% (FCF TTM 174.0m / Enterprise Value 30.28b)
FCF Margin = 0.98% (FCF TTM 174.0m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.15 (Enterprise Value 30.28b / Total Assets 26.34b)
Interest Expense / Debt = 0.93% (Interest Expense 78.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 505.2m (EBIT 739.0m * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 4.09 (Net Debt 6.47b / EBITDA 1.58b)
Debt / FCF = 37.20 (Net Debt 6.47b / FCF TTM 174.0m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 4.02% (EBIT 739.0m / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 2.68% (NOPAT 505.2m / Invested Capital 18.86b)
WACC = 5.25% (E(23.80b)/V(32.19b) * Re(6.88%) + D(8.38b)/V(32.19b) * Rd(0.93%) * (1-Tc(0.32)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 1.82%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈577.2m ; Y1≈379.0m ; Y5≈173.3m
Fair Price DCF = 3.58 (DCF Value 3.41b / Shares Outstanding 951.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 6.31 | EPS CAGR: -1.95% | SUE: 0.13 | # QB: 0
Revenue Correlation: -36.05 | Revenue CAGR: -8.07% | SUE: -0.02 | # QB: 0
Market Cap EUR = 23.80b (23.80b EUR * 1.0 EUR.EUR)
P/E Trailing = 154.875
P/E Forward = 15.1976
P/S = 1.3388
P/B = 2.2333
P/EG = 0.3634
Beta = 0.907
Revenue TTM = 17.78b EUR
EBIT TTM = 739.0m EUR
EBITDA TTM = 1.58b EUR
Long Term Debt = 7.24b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.15b EUR (from shortLongTermDebt, last quarter)
Debt = 8.38b EUR (Calculated: Short Term 1.15b + Long Term 7.24b)
Net Debt = 6.47b EUR (from netDebt column, last quarter)
Enterprise Value = 30.28b EUR (23.80b + Debt 8.38b - CCE 1.91b)
Interest Coverage Ratio = 2.49 (Ebit TTM 739.0m / Interest Expense TTM 297.0m)
FCF Yield = 0.57% (FCF TTM 174.0m / Enterprise Value 30.28b)
FCF Margin = 0.98% (FCF TTM 174.0m / Revenue TTM 17.78b)
Net Margin = 0.93% (Net Income TTM 165.0m / Revenue TTM 17.78b)
Gross Margin = 43.49% ((Revenue TTM 17.78b - Cost of Revenue TTM 10.05b) / Revenue TTM)
Gross Margin QoQ = 44.40% (prev 46.36%)
Tobins Q-Ratio = 1.15 (Enterprise Value 30.28b / Total Assets 26.34b)
Interest Expense / Debt = 0.93% (Interest Expense 78.0m / Debt 8.38b)
Taxrate = 31.64% (87.0m / 275.0m)
NOPAT = 505.2m (EBIT 739.0m * (1 - 31.64%))
Current Ratio = 1.32 (Total Current Assets 9.28b / Total Current Liabilities 7.03b)
Debt / Equity = 0.79 (Debt 8.38b / totalStockholderEquity, last quarter 10.55b)
Debt / EBITDA = 4.09 (Net Debt 6.47b / EBITDA 1.58b)
Debt / FCF = 37.20 (Net Debt 6.47b / FCF TTM 174.0m)
Total Stockholder Equity = 11.16b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.63% (Net Income 165.0m / Total Assets 26.34b)
RoE = 1.48% (Net Income TTM 165.0m / Total Stockholder Equity 11.16b)
RoCE = 4.02% (EBIT 739.0m / Capital Employed (Equity 11.16b + L.T.Debt 7.24b))
RoIC = 2.68% (NOPAT 505.2m / Invested Capital 18.86b)
WACC = 5.25% (E(23.80b)/V(32.19b) * Re(6.88%) + D(8.38b)/V(32.19b) * Rd(0.93%) * (1-Tc(0.32)))
Discount Rate = 6.88% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 1.82%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈577.2m ; Y1≈379.0m ; Y5≈173.3m
Fair Price DCF = 3.58 (DCF Value 3.41b / Shares Outstanding 951.0m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 6.31 | EPS CAGR: -1.95% | SUE: 0.13 | # QB: 0
Revenue Correlation: -36.05 | Revenue CAGR: -8.07% | SUE: -0.02 | # QB: 0